NRXS · Neuraxis, INC · Insider Trading

Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Reference is made to the 306,236 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 112,558 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

Includes (1) 21,598 shares of common stock issued to the Reporting Person as previously disclosed, and (2) 12,304 shares of common stock issued to the Reporting Person as a dividend on the Series B Preferred Stock owned by the Reporting Person.

The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

Includes (1) 286,138 shares of common stock purchased by Rosalind Master Fund L.P. in which the Reporting Person has indirect ownership as previously disclosed, and (2) 221,917 shares of common stock issued as a dividend on the Series B Preferred Stock owned by Rosalind Master Fund L.P.

Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

Reflects the weighted average price of 40,000 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on February 12, 2026 with purchase prices ranging from $4.70 to $4.95 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Reflects the weighted average price of 40,000 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on February 11, 2026 with purchase prices ranging from $4.53 to $4.85 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

21,598 shares of common stock were issued to the Reporting Person as compensation for services as independent director of the Issuer.

Includes (1) 286,138 shares of common stock owned by Rosalind Master Fund L.P., and (2) 21,598 shares of common stock issued to the Reporting Person as compensation for services as an independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

Rosalind Master Fund L.P. purchased 286,138 common shares at $3.52

Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock.

Reflects the weighted average price of 18,065 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on April 21, 2025 with purchase prices ranging from $1.60 to $1.80 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation for services as independent director of the Issuer. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person as the hiring grant. The RSUs will vest in full at the end of 36 months

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.